Patents Assigned to The Council of the Queensland Institute of Medical Research
-
Patent number: 10617738Abstract: The present disclosure relates generally to the treatment of diseases and conditions exacerbated by signalling via the erythropoietin-producing-hepatoma receptor kinases EphA4 and to agents useful in such treatment.Type: GrantFiled: October 27, 2016Date of Patent: April 14, 2020Assignees: The University of Queensland, The Council of The Queensland Institute of Medical ResearchInventors: Perry Bartlett, Andrew Boyd, Mike Gerometta, Leanne Cooper
-
Patent number: 9901632Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.Type: GrantFiled: October 21, 2013Date of Patent: February 27, 2018Assignee: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Dasari Vijayendra
-
Publication number: 20160287117Abstract: Methods and an apparatus are provided, which may be used for determining the prognosis and/or diagnosis of a subject demonstrating burst suppression, whereby the subject has or is at risk of developing brain damage. In particular, the methods and apparatus determine the prognosis and/or diagnosis through the detection of bursts from a reading of electrical and/or electromagnetic activity of the subject's brain, such as an electroencephalogram (EEG), and subsequent analysis of one or more burst metrics derived therefrom.Type: ApplicationFiled: November 20, 2014Publication date: October 6, 2016Applicant: The Council of the Queensland Institute of Medical ResearchInventors: Michael Breakspear, James Roberts, Sampsa Vanhatalo
-
Publication number: 20150273051Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.Type: ApplicationFiled: October 21, 2013Publication date: October 1, 2015Applicant: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Dasari Vijayendra
-
Patent number: 8986700Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.Type: GrantFiled: October 8, 2010Date of Patent: March 24, 2015Assignee: The Council of the Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Patent number: 8828933Abstract: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith.Type: GrantFiled: November 9, 2011Date of Patent: September 9, 2014Assignee: The Council of the Queensland Institute of Medical ResearchInventor: David Harrich
-
Patent number: 8444994Abstract: A multivalent anthelmintic vaccine targets both hookworm and schistosomiasis. The vaccine includes, at a minimum, a recombinant third-stage larval hookworm antigen, a recombinant adult stage hookworm antigen, and a recombinant schistosome antigen. Preferably, the hookworm antigens are Necator americanus antigens, although antigens from other hookworm species (e.g. Ancylostoma duodenale) may also be employed. The schistosome antigen is preferably a Schistosoma mansoni or a Schistosoma haematobium antigen although antigens from other schistosome species (e.g. Schistosoma japonicum) may also be employed. In some cases full or partial sequences of schistosome antigens may be fused with full or partial sequences of hookworm {Necator americanus) to produce recombinant chimeric antigens.Type: GrantFiled: June 30, 2009Date of Patent: May 21, 2013Assignees: The Albert B. Sabin Vaccine Institute, The George Washington University, The Council of the Queensland Institute of Medical ResearchInventors: Peter Hotez, Alexander Loukas, Mark Pearson, Jeffrey Bethony, Bin Zhan, Gaddam Goud, Maria Elena Bottazzi, David Diemert, Ami Shah Brown, Peter Giacomautonio
-
Patent number: 8367067Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.Type: GrantFiled: June 19, 2009Date of Patent: February 5, 2013Assignee: The Council of the Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Patent number: 8349575Abstract: The present invention provides a method and composition for raising an immune response in an animal. The method comprising administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety. The targeting moiety binds to at least one receptor that is upregulated on lymphocytes that home to MAdCAM+ mucosal lymphoid tissues.Type: GrantFiled: February 17, 2011Date of Patent: January 8, 2013Assignee: The Council of the Queensland Institute of Medical Research (QIMR)Inventors: Brent Steven McKenzie, Jefferey Stephen Boyle, Andrew Mark Lew
-
Patent number: 8206725Abstract: The present invention relates to an immunogenic agent comprising a low dose of an antigenic component from one or more pathogens and an agent capable of increasing an amount of IL-12 in animal, and use thereof for reducing infection or improving recovery from an infection from the pathogen. The immunogenic agent preferably comprises CpG nucleic acid, IL-12 protein and/or IL-12 nucleic acid. The pathogen is preferably an intracellular pathogen comprising one or more species and strains, such as Plasmodium spp. The invention also relates to a pharmaceutical composition comprising the immunogenic agent. The pharmaceutical composition is preferably an immunotherapeutic composition. The immunotherapeutic composition, is preferably a vaccine capable of providing protection against or treating Plasmodium spp infection, the causative agent of malaria in humans.Type: GrantFiled: June 30, 2004Date of Patent: June 26, 2012Assignees: The Council of the Queensland Institute of Medical Research, McGill UniversityInventors: Michael Good, Mary M Stevenson
-
Publication number: 20120115775Abstract: Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith.Type: ApplicationFiled: November 9, 2011Publication date: May 10, 2012Applicant: The Council of the Queensland Institute of Medical ResearchInventor: David Harrich
-
Patent number: 8097430Abstract: The present invention provides a method of raising an immune response in an animal. The method comprises administering to the animal a composition comprising a carrier and an antigen bound to a targeting moiety wherein the targeting moiety binds to at least one receptor present in circulatory vessels in Gut Associated Lymphoid Tissue. It is preferred that the targeting moiety binds to Mucosal Addressin Cellular Adhesion Molecule-1.Type: GrantFiled: May 24, 2002Date of Patent: January 17, 2012Assignee: The Council of Queensland Institute of Medical ResearchInventors: Brent McKenzie, Jefferey Boyle, Andrew Lew
-
Publication number: 20110280899Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.Type: ApplicationFiled: October 8, 2010Publication date: November 17, 2011Applicant: The Council of The Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Patent number: 7976845Abstract: An isolated protein construct comprising a polyepitope derived from multiple human cytomegalovirus protein antigen epitopes conjugated to an extracellular domain of glycoprotein B, which isolated protein is capable of eliciting a cytotoxic T-lymphocyte immune response as well as a neutralizing antibody response to human cytomegalovirus. Also provided are pharmaceutical compositions comprising the isolated protein or an adenoviral expression construct for delivery and expression of a nucleic acid encoding the isolated protein for prophylactic and/or therapeutic treatment of human cytomegalovirus infection, particularly in humans.Type: GrantFiled: November 29, 2005Date of Patent: July 12, 2011Assignee: The Council of the Queensland Institute of Medical ResearchInventor: Rajiv Khanna
-
Publication number: 20110158998Abstract: A helminth protein immunogen is described. Included as the immunogen is an isolated protein comprising an immunogenic, extracellular fragment of a schistosome tegument protein selected from the group consisting of a TSP-1 protein; a TSP-2 protein; and a 7TM protein. An antibody which binds the isolated protein is also described. Additionally, an immunotherapeutic composition comprising the immunogenic protein and an immunologically acceptable carrier, diluent or excipient is described. Furthermore, a vaccine comprising the immunogenic protein is described. Also described are an isolated nucleic acid that encodes the immunogenic protein and a genetic construct comprising that isolated nucleic acid. Further, a host cell comprising the genetic construct is described. A method of immunizing against schistosomiasis including the step of administering the immunotherapeutic composition to an animal is also described.Type: ApplicationFiled: June 9, 2006Publication date: June 30, 2011Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCHInventors: Alexander Constantine Loukas, Mai Tran, Malcolm Kenneth Jones, Danielle Julianna Smyth, Donald Peter Mcmanus, Mark Simon Pearson, Jeffrey Michael Bethony
-
Patent number: 7897570Abstract: The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.Type: GrantFiled: January 14, 2008Date of Patent: March 1, 2011Assignees: The Walter and Eliza Hall Institute of Medical Research, The Council of the Queensland Institute of Medical Research, The University of MelbourneInventors: Perry F. Bartlett, Lynne Hartley, Mark Pouzzotto, Trevor Kilpatrick, Frank Kontgen, Jason Coonan, Ursula Greferath, Andrew W. Boyd, Mirella Dottori, Mary P. Galea, George Paxinos, Mark Murphy
-
Publication number: 20100297623Abstract: A method for detecting transformed cells or tumour cells, a method for diagnosing or prognosing cancer or for assessing a predisposition to cancer, and kits for use in the methods are disclosed. The methods particularly involve the detection of overexpression of an ssDNA binding protein (SSB) or polypeptide comprising the following amino acid sequence: FX1X2DX3KPGLKNLNX4X5FIVLEX6GRVTKTKDGHEVRX7CKVADKTGSIX8ISVWDX9X10GX11LIQPGDI IRLTX12GYASX13X14KGCLTLYTGRGGX15LQKIGEFCMVYSEVPNFSEPNPX16YX17 X18QQ (SEQ ID NO: 1).Type: ApplicationFiled: March 7, 2008Publication date: November 25, 2010Applicant: THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCHInventors: Kum Kum Khanna, Derek Richard, Malcolm F. White
-
Patent number: 7833532Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope.Type: GrantFiled: August 12, 2003Date of Patent: November 16, 2010Assignee: The Council of The Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng
-
Publication number: 20100183647Abstract: The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the must commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine compositions comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject.Type: ApplicationFiled: March 16, 2009Publication date: July 22, 2010Applicant: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Rebecca Ann Elkington, Susan Jennifer Walker
-
Publication number: 20100092500Abstract: The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.Type: ApplicationFiled: June 19, 2009Publication date: April 15, 2010Applicant: The Council of The Queensland Institute of Medical ResearchInventors: David Jackson, Weiguang Zeng